A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis.

Trial Profile

A Multicenter, Randomized Study of the Efficacy and Safety of NVC-422 Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2016

At a glance

  • Drugs Auriclosene (Primary)
  • Indications Adenovirus infections; Infectious conjunctivitis
  • Focus Therapeutic Use
  • Acronyms BAYnovation
  • Sponsors NovaBay Pharmaceuticals
  • Most Recent Events

    • 27 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 10 Jul 2014 NovaBay Pharmaceuticals expects to report topline results of this trial by mid-August 2014.
    • 01 May 2014 According to a NovaBay Pharmaceuticals media release, the results of this trial are expected in mid-2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top